In terms of prognosis, research found that increasing levels of exomiR-96 were associated with advanced tumor stage and grade, as well as lymph node metastasis in lung cancer patients, and that disease progression was controlled by exomiR-96 by targeting the tumor-suppressor LIM-domain-only protein 7 (LMO7) [26]. Here, LMO7 is linked to metastatic malignant neoplasm in the lymph nodes.